ATCO Pharma successfully hosted a dedicated Atcocoxib & Gralipentin XR Standalone Meeting from 17 to 20 June 2026 at Stella Gardens Resort, Hurghada, Egypt. The meeting brought together distinguished experts in orthopedics and neurology for a focused scientific exchange on contemporary approaches to pain management and patient care.
The scientific meeting featured an outstanding panel of academic leaders and guest speakers, providing a multidisciplinary perspective on the management of musculoskeletal and neuropathic pain.
The meeting was chaired by Prof. Hossam Gad, Head of the Orthopaedic Surgery Department at Kafr El Sheikh University, and Prof. Rasha Kabbany, Former Head of the Neurology Department at Menoufia University.
The scientific program also welcomed two distinguished guest speakers: Prof. Hesham Elkady, Professor of Orthopedic Surgery & Arthroscopy at Assiut University, and Prof. Ayman Nassif, Professor of Neurology at Ain Shams University.
The orthopedic session focused on the management of knee osteoarthritis and the value of pre-emptive analgesia in orthopedic surgery, highlighting the importance of effective pain management strategies across the patient journey.
Complementing the orthopedic perspective, the neurology session addressed neuropathic pain, from mechanisms to treatment, offering an overview of the clinical considerations involved in understanding and managing this complex pain condition.
The scientific program was supported by ATCO Pharma’s relevant therapeutic portfolio, including Atcocoxib (Etoricoxib 60 & 90 mg), Gralipentin XR (Gabapentin 300 & 600 mg), and Eperical (Eperisone 50 & 100 mg).
Through this standalone meeting, ATCO Pharma reinforced its commitment to scientific engagement, continuous medical education, and advancing meaningful discussions around pain management. By bringing together leading experts from different specialties, the event created a valuable platform for exchanging clinical perspectives and exploring comprehensive approaches to patients living with acute, musculoskeletal, and neuropathic pain.
The meeting reflects ATCO Pharma’s continued focus on supporting healthcare professionals with scientifically driven initiatives that contribute to better understanding and management of pain-related conditions.